• Pau Riera, Berta Martín-Cullell, Anna de Dios, Anna C Virgili, Lucía Ramírez, and David Páez.
• Servicio de Farmacia, Hospital de la Santa Creu i Sant Pau, Barcelona, España; Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, España; CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, España. Electronic address: priera@santpau.cat.
• Med Clin (Barc). 2025 Jan 25.

Background And AimOne third of patients with colorectal cancer (CRC) undergoing chemotherapy develop serious adverse effects. The aim was to monitor toxicities, evaluate quality of life and the usefulness of the EMMA Salud mobile App in these patients.Patients And MethodsProspective single-center study including patients with CRC who started fluoropyrimidine-based chemotherapy treatment between 02/2022 and 02/2023. Through the mobile application, patients could record adverse effects, interact with healthcare professionals and answer quality of life (EORTC-CRC) and anxiety/depression (HADS) questionnaires.ResultsA total of 31 patients were included. Regarding the use of the App, 10 patients (32.2%) recorded variables of interest, 11 (35.5%) recorded toxicities and 10 (32.2%) sent direct messages to healthcare professionals. Many patients (48%) also used the telephone consultation from the nurse case manager. The response rate to HADS and EORTC-CRC was 30% at baseline and 10% at approximately 6 months.ConclusionsMonitoring toxicities through a mobile application can improve communication in motivated patients who adhere to new technologies. However, the role of the nurse case manager continues to be a valuable resource.Copyright © 2025 Elsevier España, S.L.U. All rights reserved.

8 keywords...

hide…